Stocktoria
Shattuck Labs, Inc. STTK
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-09
Shattuck Labs, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.0M | $5.7M | $1.7M | $652,000 | $30.0M |
| R&D expense | $35.3M | $67.2M | $74.3M | $82.9M | $56.6M |
| Operating income | -$51.5M | -$80.6M | -$92.0M | -$103.3M | -$45.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$48.8M | -$75.4M | -$87.3M | -$101.9M | -$45.0M |
| EPS (diluted) | $-0.70 | $-1.49 | $-2.05 | $-2.41 | $-1.07 |
| Operating cash flow | -$39.9M | -$60.5M | -$81.2M | -$94.5M | -$57.1M |
| Free cash flow | -$40.0M | -$60.6M | -$81.6M | -$106.1M | -$65.0M |
| Cash & equivalents | $54.2M | $57.4M | $125.6M | $47.4M | $92.3M |
| Total assets | $91.0M | $91.0M | $159.6M | $205.3M | $298.6M |
| Total liabilities | $8.6M | $11.4M | $14.9M | $29.2M | $26.8M |
| Shareholders' equity | $82.4M | $79.6M | $144.7M | $176.2M | $271.8M |
Source: SEC EDGAR filings · CIK 0001680367 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.